Want to see CRNX full AI Analyst Report?

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

808 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRNX Analyst Ratings

Hold

2 Buy

12 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Crinetics

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRNX Stock 12 Month Forecast

Average Price Target

$85.56

▲(2.18% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $85.56 with a high forecast of $95.00 and a low forecast of $80.00. The average price target represents a 2.18% change from the last price of $83.73.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","61":"$61","96":"$96","43.5":"$43.5","78.5":"$78.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.55555555555554,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$85.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,43.5,61,78.5,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.52,84.40307692307692,85.28615384615384,86.16923076923077,87.05230769230769,87.9353846153846,88.81846153846153,89.70153846153846,90.58461538461539,91.4676923076923,92.35076923076923,93.23384615384616,94.11692307692307,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.52,83.6765811965812,83.83316239316238,83.98974358974358,84.14632478632478,84.30290598290597,84.45948717948717,84.61606837606837,84.77264957264957,84.92923076923076,85.08581196581196,85.24239316239316,85.39897435897434,{"y":85.55555555555554,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.52,83.24923076923076,82.97846153846153,82.7076923076923,82.43692307692308,82.16615384615385,81.89538461538461,81.62461538461538,81.35384615384615,81.08307692307692,80.8123076923077,80.54153846153847,80.27076923076923,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.35,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.57,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.02,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.52,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.68,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.52,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$95.00

Average Price Target$85.56

Lowest Price Target$80.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ashwani Verma

UBS

$55→$85

Hold

1.52%

Upside

Downgraded

07/28/26

Crinetics downgraded to Neutral from Buy at UBSCrinetics downgraded to Neutral from Buy at UBS

Kate Dellorusso

LifeSci Capital

$85

Hold

1.52%

Upside

Reiterated

07/11/26

Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (NASDAQ: VERA), Crinetics Pharmaceuticals (NASDAQ: CRNX) and Revolution Medicines (NASDAQ: RVMD)

Alex Thompson CFA

Stifel Nicolaus

$83→$85

Hold

1.52%

Upside

Downgraded

07/08/26

Crinetics downgraded to Hold from Buy at StifelCrinetics downgraded to Hold from Buy at Stifel

Gavin Clark-Gartner

Evercore ISI

$88→$85

Hold

1.52%

Upside

Downgraded

07/08/26

Crinetics downgraded to In Line from Outperform at Evercore ISICrinetics downgraded to In Line from Outperform at Evercore ISI

Tyler Van Buren

TD Cowen

―

Hold

―

Downgraded

07/07/26

Crinetics Pharmaceuticals (CRNX) Receives a New Rating from a Top Analyst

Yasmeen Rahimi

Piper Sandler

―

Hold

―

Downgraded

07/07/26

Crinetics downgraded to Neutral from Overweight at Piper SandlerCrinetics downgraded to Neutral from Overweight at Piper Sandler

Douglas Tsao

H.C. Wainwright

$81→$85

Hold

1.52%

Upside

Downgraded

07/07/26

Crinetics downgraded to Neutral from Buy at H.C. WainwrightCrinetics downgraded to Neutral from Buy at H.C. Wainwright

Jonathan Wolleben

Citizens JMP

―

Hold

―

Downgraded

07/07/26

Crinetics downgraded to Market Perform from Outperform at CitizensCrinetics downgraded to Market Perform from Outperform at Citizens

Catherine Novack

JonesTrading

$97→$85

Hold

1.52%

Upside

Downgraded

07/07/26

Crinetics downgraded to Hold from Buy at JonesResearchCrinetics downgraded to Hold from Buy at JonesResearch

Dennis Ding

Jefferies

$55→$85

Hold

1.52%

Upside

Downgraded

07/07/26

Crinetics downgraded to Hold from Buy at JefferiesCrinetics downgraded to Hold from Buy at Jefferies

Leland Gershell

Oppenheimer

―

Hold

―

Downgraded

07/07/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX), Opus Genetics (NASDAQ: IRD) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Joshua Schimmer

Cantor Fitzgerald

―

Hold

―

Downgraded

07/06/26

Crinetics downgraded to Neutral from Overweight at Cantor FitzgeraldCrinetics downgraded to Neutral from Overweight at Cantor Fitzgerald

Maxwell Skor

Morgan Stanley

$87→$80

Buy

-4.45%

Downside

Reiterated

06/15/26

Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Pharvaris (PHVS)

Joseph Schwartz

Leerink Partners

$95

Buy

13.46%

Upside

Reiterated

06/11/26

Leerink sees favorable readthrough to Crinetics after Camurus' Oclaiz CRLLeerink sees favorable readthrough to Crinetics after Camurus' Oclaiz CRL

Richard Law CFA

Goldman Sachs

$67

Buy

-19.98%

Downside

Reiterated

03/01/26

Goldman Sachs Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ashwani Verma

UBS

$55→$85

Hold

1.52%

Upside

Downgraded

07/28/26

Crinetics downgraded to Neutral from Buy at UBSCrinetics downgraded to Neutral from Buy at UBS

Kate Dellorusso

LifeSci Capital

$85

Hold

1.52%

Upside

Reiterated

07/11/26

Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (NASDAQ: VERA), Crinetics Pharmaceuticals (NASDAQ: CRNX) and Revolution Medicines (NASDAQ: RVMD)

Alex Thompson CFA

Stifel Nicolaus

$83→$85

Hold

1.52%

Upside

Downgraded

07/08/26

Crinetics downgraded to Hold from Buy at StifelCrinetics downgraded to Hold from Buy at Stifel

Gavin Clark-Gartner

Evercore ISI

$88→$85

Hold

1.52%

Upside

Downgraded

07/08/26

Crinetics downgraded to In Line from Outperform at Evercore ISICrinetics downgraded to In Line from Outperform at Evercore ISI

Tyler Van Buren

TD Cowen

―

Hold

―

Downgraded

07/07/26

Crinetics Pharmaceuticals (CRNX) Receives a New Rating from a Top Analyst

Yasmeen Rahimi

Piper Sandler

―

Hold

―

Downgraded

07/07/26

Crinetics downgraded to Neutral from Overweight at Piper SandlerCrinetics downgraded to Neutral from Overweight at Piper Sandler

Douglas Tsao

H.C. Wainwright

$81→$85

Hold

1.52%

Upside

Downgraded

07/07/26

Crinetics downgraded to Neutral from Buy at H.C. WainwrightCrinetics downgraded to Neutral from Buy at H.C. Wainwright

Jonathan Wolleben

Citizens JMP

―

Hold

―

Downgraded

07/07/26

Crinetics downgraded to Market Perform from Outperform at CitizensCrinetics downgraded to Market Perform from Outperform at Citizens

Catherine Novack

JonesTrading

$97→$85

Hold

1.52%

Upside

Downgraded

07/07/26

Crinetics downgraded to Hold from Buy at JonesResearchCrinetics downgraded to Hold from Buy at JonesResearch

Dennis Ding

Jefferies

$55→$85

Hold

1.52%

Upside

Downgraded

07/07/26

Crinetics downgraded to Hold from Buy at JefferiesCrinetics downgraded to Hold from Buy at Jefferies

Leland Gershell

Oppenheimer

―

Hold

―

Downgraded

07/07/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX), Opus Genetics (NASDAQ: IRD) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Joshua Schimmer

Cantor Fitzgerald

―

Hold

―

Downgraded

07/06/26

Crinetics downgraded to Neutral from Overweight at Cantor FitzgeraldCrinetics downgraded to Neutral from Overweight at Cantor Fitzgerald

Maxwell Skor

Morgan Stanley

$87→$80

Buy

-4.45%

Downside

Reiterated

06/15/26

Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Pharvaris (PHVS)

Joseph Schwartz

Leerink Partners

$95

Buy

13.46%

Upside

Reiterated

06/11/26

Leerink sees favorable readthrough to Crinetics after Camurus' Oclaiz CRLLeerink sees favorable readthrough to Crinetics after Camurus' Oclaiz CRL

Richard Law CFA

Goldman Sachs

$67

Buy

-19.98%

Downside

Reiterated

03/01/26

Goldman Sachs Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crinetics Pharmaceuticals

3 Months

Brian SkorneyRobert W. Baird

Success Rate

11/14 ratings generated profit

Average Return

+19.39%

Copying Brian Skorney's trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +19.39% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

13/20 ratings generated profit

Average Return

+50.98%

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +50.98% per trade.

2 Years

Joseph SchwartzLeerink Partners

Success Rate

17/20 ratings generated profit

Average Return

+77.13%

Copying Joseph Schwartz's trades and holding each position for 2 Years would result in 85.00% of your transactions generating a profit, with an average return of +77.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRNX Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRNX has received 5 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. CRNX average Analyst price target in the past 3 months is 85.56.

Each month's total comprises the sum of three months' worth of ratings.

CRNX Financial Forecast

CRNX Earnings Forecast

Next quarter’s earnings estimate for CRNX is -$1.18 with a range of -$1.35 to -$0.87. The previous quarter’s EPS was -$1.23. CRNX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year CRNX has its overall industry.

CRNX Sales Forecast

Next quarter’s sales forecast for CRNX is $14.84M with a range of $12.50M to $16.59M. The previous quarter’s sales results were $10.73M. CRNX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year CRNX has its overall industry.

CRNX Stock Forecast FAQ

What is CRNX’s average 12-month price target, according to analysts?

Based on analyst ratings, Crinetics Pharma’s 12-month average price target is 85.56.

What is CRNX’s upside potential, based on the analysts’ average price target?

Crinetics Pharma has 2.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRNX a Buy, Sell or Hold?

Crinetics Pharma has a consensus rating of Hold which is based on 2 buy ratings, 12 hold ratings and 0 sell ratings.

What is Crinetics Pharma’s price target?

The average price target for Crinetics Pharma is 85.56. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $95.00 ,the lowest forecast is $80.00. The average price target represents 2.18% Increase from the current price of $83.73.

What do analysts say about Crinetics Pharma?

Crinetics Pharma’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of CRNX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

CRNX Analyst Ratings

CRNX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Crinetics Pharmaceuticals

CRNX Analyst Recommendation Trends

CRNX Financial Forecast

CRNX Earnings Forecast

CRNX Sales Forecast

CRNX Stock Forecast FAQ

Detailed List of Analyst Forecasts